SERCA2a gene therapy in heart failure: an anti-arrhythmic positive inotrope.
about
The effect of injection speed and serial injection on propidium iodide entry into cultured HeLa and primary neonatal fibroblast cells using lance array nanoinjection.Inhibition of late sodium current suppresses calcium-related ventricular arrhythmias by reducing the phosphorylation of CaMK-II and sodium channel expressionsState-of-the-art human gene therapy: part II. Gene therapy strategies and clinical applications.SERCA2 Haploinsufficiency in a Mouse Model of Darier Disease Causes a Selective Predisposition to Heart FailureOphiopogonin D maintains Ca2+ homeostasis in rat cardiomyocytes in vitro by upregulating CYP2J3/EETs and suppressing ER stress.Overexpression of Sarcoendoplasmic Reticulum Calcium ATPase 2a Promotes Cardiac Sympathetic Neurotransmission via Abnormal Endoplasmic Reticulum and Mitochondria Ca2+ Regulation.Nitroxyl (HNO) for treatment of acute heart failure.New Targets in the Drug Treatment of Heart Failure.Mendelian Disorders of Cornification Caused by Defects in Intracellular Calcium Pumps: Mutation Update and Database for Variants in ATP2A2 and ATP2C1 Associated with Darier Disease and Hailey-Hailey Disease.Mitochondrial pathways to cardiac recovery: TFAM.Pyk2 inhibition promotes contractile differentiation in arterial smooth muscle.Intramyocardial injection of SERCA2a-expressing lentivirus improves myocardial function in doxorubicin-induced heart failure.Mechanisms of TFAM-mediated cardiomyocyte protection.LncRNA ZFAS1 as a SERCA2a Inhibitor to Cause Intracellular Ca2+ Overload and Contractile Dysfunction in a Mouse Model of Myocardial Infarction.
P2860
Q30378182-9F76F3C4-D944-44A5-8724-242D5BF98DCAQ33681289-92C76201-A022-404E-905A-B953C8447059Q34664690-03E637B4-9951-4A8B-8C47-E159A924E083Q35612469-264AD025-F51C-4F19-9143-3E956A79FE5CQ35912519-1CDD0080-FC11-4576-A9DC-9360AB14E908Q37691385-3B79EE27-5017-45DE-B7D9-9142CCE12AB0Q38224809-3C5C9878-5556-4289-8774-E7AF9943E0BAQ38667210-2384FB8B-F282-464F-84A7-FF1E4F3DF47CQ38776309-C10B878E-726A-4A32-A450-ADF3C21461CCQ41980044-2224F606-1CAB-4B06-AD12-C22F3B379112Q42503512-AAA1C8CD-C096-4C65-8729-DE49D5668DB0Q45886178-75A75785-5CE3-4A59-B632-978CA0FD28D6Q46322285-AF40B9F8-F2C7-4D64-8B25-C752899AC567Q52687730-5E7AC00F-24E4-4E5D-AD47-8409AB785579
P2860
SERCA2a gene therapy in heart failure: an anti-arrhythmic positive inotrope.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
SERCA2a gene therapy in heart failure: an anti-arrhythmic positive inotrope.
@en
SERCA2a gene therapy in heart failure: an anti-arrhythmic positive inotrope.
@nl
type
label
SERCA2a gene therapy in heart failure: an anti-arrhythmic positive inotrope.
@en
SERCA2a gene therapy in heart failure: an anti-arrhythmic positive inotrope.
@nl
prefLabel
SERCA2a gene therapy in heart failure: an anti-arrhythmic positive inotrope.
@en
SERCA2a gene therapy in heart failure: an anti-arrhythmic positive inotrope.
@nl
P2093
P2860
P356
P1476
SERCA2a gene therapy in heart failure: an anti-arrhythmic positive inotrope
@en
P2093
Alexander R Lyon
Carl Hayward
Kenneth T MacLeod
P2860
P356
10.1111/BPH.12472
P407
P577
2014-01-01T00:00:00Z